Shengbo Zhang et al. examined that CCL5-deficiency could upregulate PD-1 and PD-L1 expression and reduce the resistance to anti-PD-1 antibody therapy in the CRC mouse model [7]. The gene discussed is CCL5; the disease is colorectal carcinoma.